Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C Mutated Solid Tumors
Study of RMC-6291 and RMC 6236 in Patients with Solid Tumors
Sponsor: Revolution Medicines
Enrolling: Male and Female Patients
IRB Number: AAAU8909
U.S. Govt. ID: NCT06128551
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to test a combination of 2 new drugs called RMC-6291 and RMC 6236 (the study drugs). RMC-6291 and RMC-6236 are new investigational (ie, experimental) drugs, which means that they are not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC 6291 and RMC-6236 will be tested together in humans. This study will test the safety and anti-tumor effects of RMC-6291 and RMC-6236 when given together at different doses in participants with a change or alteration in the KRASG12C gene within the cells that make up their tumor. How a participant's body processes RMC-6291 and RMC-6236 when they are given together will also be tested. Cancer include: bladder cancer, breast cancer, colon and rectal cancer, esophageal cancer, gynecologic cancers, head and neck/oral cancer, kidney cancer, liver cancer, lung cancer, melanoma, pancreatic cancer, prostate cancer, stomach cancer, testicular cancer, and thyroid cancer.
Benjamin Herzberg, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Are you able to swallow medications? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator